English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, December 18, 2020
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial
Friday, November 13, 2020
陈力博士受邀参加浦东开放30周年庆祝大会
陳力博士受邀參加浦東開放30周年慶祝大會
Wednesday, October 14, 2020
华领医药宣布获得《药品生产许可证》
華領醫藥宣佈獲得《藥品生產許可證》
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin
Monday, August 17, 2020
拜耳与华领医药宣布在糖尿病领域建立战略合作 双方就处于临床试验阶段的首创糖尿病治疗药物dorzagliatin在中国达成商业合作协议
拜耳與華領醫藥宣佈在糖尿病領域建立戰略合作 雙方就處於臨床試驗階段的首創糖尿病治療藥物dorzagliatin在中國達成商業合作協議
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China
Wednesday, July 1, 2020
华领医药宣布Dorzagliatin与二甲双胍联合用药III期注册临床研究24周核心研究取得正面结果

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575